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Purpose: Exosomes isolated from the plasma of newly diagnosed acute myeloid leukemia
(AML) patients have elevated protein and transforming growth factor-beta 1 (TGF-β1) con-
tents and inhibit natural killer (NK) cell cytotoxicity (Haematologica 96, p. 1302, 2011). A
potential role of exosomes in predicting responses to chemotherapy (CT) was evaluated in
AML patients undergoing treatment.
Experimental Design: Plasma was obtained from AML patients at diagnosis (n=16); post-
induction CT (n=9); during consolidation CT (n=10); in long-term remission (Lt-CR, n= 5);
and from healthy volunteers (n=7). Exosomes were isolated by size-exclusion chromatog-
raphy and ultracentrifugation. The exosomal protein, soluble TGFβ-1 levels (ELISA), and
the TGF-β1 profiles (western blots) were compared among patients’ cohorts. The results
were correlated with the patients’ cytogenetic profile, percentage of leukemic blast, and
outcome.
Results: At diagnosis, protein and TGF-β1 levels were higher (p<0.009 and p<0.004)
in AML than control exosomes. These values decreased after induction CT (p<0.05 and
p<0.004), increased during consolidation CT (p<0.02 and p<0.005), and normalized in
Lt-CR. While TGF-β1 and protein levels tracked one another, TGF-β1 pro-peptide, latency-
associated peptide (LAP), or mature TGF-β1 differentially decorated exosomes isolated
before, during, and after CT. Only TGF-β1 pro-peptide was seen in exosomes of controls
or Lt-CR patients. During consolidation CT, exosomes carriedTGF-β1 pro-peptide, LAP, and
low levels of mature TGF-β1. NK cell co-incubation with AML exosomes carrying all three
TGF-β1 forms induced down-regulation of NKG2D expression.
Conclusion: Changes in exosomal protein and/or TGF-β1 content may reflect responses
to CT. The exosomal profile may suggest the presence of residual disease in patients
considered to have achieved complete remission.
Keywords: acute myelogenous leukemia, exosomes,TGF-β1, protein levels, chemotherapy
INTRODUCTION
Sixty to eighty percent of adult patients with newly diagnosed
acute myeloid leukemia (AML) attain a complete remission (CR)
with intensive induction chemotherapy [CT; Ref. (1, 2)]. However,
without additional cytotoxic therapy, virtually all of these patients
relapse. Post-remission therapy aims to destroy leukemia cells that
survive induction CT but are undetectable by conventional meth-
ods. Ascertaining whether a patient in CR is destined to remain
clinically disease free is limited by the inherent insensitivity of
currently available tests for detecting residual leukemia and by the
likelihood that the small area of bone marrow examined does not
reflect the potential involvement of the entire, much larger, bone
marrow compartment.
Exosomes are virus-size (30–100 nm in diameter) membrane-
bound microvesicles that are formed within the endocytic com-
partments and via fusion of multivesicles bodies with the cell
membrane are released into the extracellular space (3). While
exosome secretion occurs under physiologic conditions, and all
cells are capable of their release, tumor cells are avid exosome
producers. The exosome fractions obtained from plasma of can-
cer patients are enriched in various immunosuppressive molecules
and in proteins/glycoproteins expressed on cell membranes and/or
in the cytosol of the parent tumor cells. In AML, we reported highly
elevated exosome plasma levels in newly diagnosed untreated AML
patients compared to the levels measured in normal controls [NC;
Ref. (4)].
Based on the potential role of tumor-derived exosomes (TEXs)
as mediators of tumorigenesis (5–7), we reasoned that exosome
plasma levels and especially the molecular content of isolated exo-
somes, which are thought to mimic that of leukemic blasts, could
be informative about the presence in the bone marrow of leukemic
blasts that might avoid detection by conventional hematopatho-
logical assays. Therefore, studies of blast-derived exosomes in
the plasma of patients at the time of initial AML diagnosis and,
www.frontiersin.org April 2014 | Volume 5 | Article 160 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hong et al. Exosomes in AML therapy
especially, of changes in the exosomal profile during and after con-
solidation CT, might substantially increase our ability to identify
AML patients at the highest risk for relapse. To test this hypothesis,
we isolated and studied exosomal fractions obtained from plasma
of various cohorts of AML patients in a cross-sectional study. We
report here that changes in total exosomal protein levels and the
presence of different forms of transforming growth factor-beta 1
(TGF-β1) carried by AML exosomes reflect effects of therapy and
might serve as indicators of leukemic relapse in AML patients.
In addition, AML exosomes carrying an active form of TGF-β1
induced down-regulation of NKG2D expression in normal natural
killer (NK) cells.
MATERIALS AND METHODS
PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HEALTHY
VOLUNTEERS
Samples of venous blood (20–50 mL) were obtained from 16
patients newly diagnosed with AML and prior to any treatment.
In addition, samples were obtained from 9 patients on day 14
after starting induction CT with anthracycline and cytarabine,
10 patients undergoing consolidation CT with a high dose of
cytarabine, and 5 patients in a long-term remission following con-
solidation CT. Venous blood was also collected from age-matched
healthy volunteers (n= 7). Peripheral blood was collected into
heparinized vacutainer tubes, and the samples were hand-carried
to the laboratory, processed, and either immediately used for
experiments or aliquoted and frozen at−80°C. All subjects partic-
ipating in this cross-sectional study signed an informed consent
approved by the Institutional Review Board of the University of
Pittsburgh. The AML patients were grouped into three cytogenetic
risk categories based on published criteria (8, 9). The favorable
risk category included patients with abnormalities (abn) of inv
(16)/t (16;16)/del(16q) or t (8;21) without either a del(9q) or being
a part of the more complex karyotype. The intermediate-risk cat-
egory included patients characterized by+8,−Y,+6, del (12p), or
a normal karyotype. The unfavorable risk category was defined by
the presence of one or more of −5/del(5q), −7/del(7q), inv(3q),
abn 11q, 20q, or 21q, del(9q), t (6;9), t (9;22), abn 17p, or the more
complex karyotype defined as three or more abnormalities.
ISOLATION OF EXOSOMES
Exosomes were isolated from plasma of NC or AML patients
using differential centrifugation, size-exclusion chromatography
on Sephadex G50 columns, and ultracentrifugation, as previously
described (10). Briefly, aliquots of plasma (up to 9 mL) were cen-
trifuged at 1000× g for 10 min, filtered with 0.22µm syringe
filter unit, centrifuged again at 10,000× g for 30 min, applied
to an A50m column (Bio-Rad Laboratories, Hercules, CA, USA),
packed with Sepharose 2B (Sigma-Aldrich, St. Louis, MO, USA),
and were eluted with phosphate buffered saline (PBS). The pro-
tein content was monitored by measuring absorbance at 280 nm.
Fractions between 10 and 28 mL (the void volume peak) con-
tained>50,000 kDa proteins and exosomes. Three 9 mL fractions
were collected, and after discarding the first fraction, the second
and third fractions were combined, placed in a Beckman Optiseal
Centrifuge Tube and centrifuged in a Beckman Optima LE-80K
Ultracentrifuge (Beckman Coulter) at 100,000× g for 2 h at 4°C.
The pelleted exosomes were resuspended in PBS (200µL) and
analyzed using a Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, CA, USA). The protein content of all final exosomal frac-
tions was normalized to 1 mL plasma, and the data are presented
in microgram exosomal proteins/milliliter plasma.
CHARACTERIZATION OF AML PLASMA-DERIVED EXOSOMES
To show that fractions recovered from plasma as described above
contained exosomes, we subjected the pellet content to contin-
uous sucrose gradient (0.25–2.5 M) centrifugation as previously
described (11) Serial 1 mL fractions at an increasing sucrose den-
sity were collected and evaluated by western blots for expression of
exosomal markers, CD81 (Figure 1A) and LAMP-1 (not shown),
by using antibodies specific for these proteins. In addition, iso-
lated exosomes were visualized by negative staining with 1%
uranyl acetate in water using a transmission electron microscope
(Figure 1B), and their size and density were determined using
a NanoSight instrument (Figure 1C). Finally, isolated exosomes
were captured on 9.1µM beads coated with streptavidin and
biotinylated anti-CD81 antibody and were visualized and quan-
tified by flow cytometry using the EXO-FITC dye (all from SBI,
Mountain View, CA, USA; Figure 1D). In all procedures utilizing
antibodies, isotype control antibodies were included.
WESTERN BLOTS
Isolated exosomes were characterized for expression of TGFβ-1
pro-peptide, latency-associated protein (LAP), mature TGFβ-1,
CD9, CD81, CD34, CD117, and GAPDH using western blots
as previously described (4). Aliquots (10µg) of isolated exo-
somes were lysed with Laemmli sample buffer (Bio-Rad Lab-
oratories, Hercules, CA, USA), separated on 7–15% SDS/PAGE
gels, and transferred onto PVDF membrane (Millipore, Biller-
ica, MA, USA) for western blot analysis. Membranes were incu-
bated with antibodies of TGF-β1, which detect TGF-β1 pro-
peptide, LAP, and mature TGF-β1 (1:1000, Cell Signaling #3711;
1: 2000, R&D Systems AF-264-NA or AF-101-NA), CD9 (1:500,
Abcam, ab65230), CD34 (1:2000, Abcam, ab81289) and c-kit
(1:100, Abcam, ab5506), CD81 (1:200, Thermo Fisher, PA5-
13582), or GAPDH (1:500, Santa Cruz, FL-335) for overnight
in 4°C and then with the HRP-conjugated secondary antibody
(1:5000, Pierce Chemical) for 1 h at room temperature (RT) and
developed with ECL western blotting detection reagents (GE
Healthcare Biosciences, Pittsburgh, PA, USA). The intensities of
the bands on exposed films were semi-quantified using Image J
software (NIH).
ELISA FOR TGF-β1
Levels of TGFβ-1 in patients’ plasma or in exosomal fractions were
quantified using a Quantikine ELISA kit purchased from R&D
Systems, Minneapolis, MA, USA. Prior to ELISA, exosomes were
sonicated to release membrane-bound TGF-β1 and then acidified
to activate latent TGF-β1. Isolated exosome fractions were first
sonicated using five 2-s bursts at 35 W in a sonicator bath (Lab-line
Instruments, Melrose Park, IL, USA). Samples were then acidified
with 1 N HCl (40µL sample plus 20µL HCl) for 10 min at RT and
neutralized with an equal volume (20µL) of 1.2 N NaOH/0.5 M
HEPES. Acidified samples were diluted 1:10 and 1:20 in PBS prior
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FIGURE 1 | Characteristics of exosomes isolated from AML plasma.
(A) A representative western blot of exosomes floated on a continuous
sucrose gradient. Individual 1 mL fractions were collected and after
ultracentrifugation were loaded on gels for electrophoresis. Exosomes
expressing CD81 and TGF-β1 are located in fractions 6 and 7.
(B) Transmission electron microscopy of exosomes collected from the
sucrose gradient shown in (A) as fraction #6, negative stain with uranyl
acetate. (C) Exosomes in fraction #6 were examined in a NanoSight
instrument to determine their size and particle concentration. (D) Flow
cytometry of AML plasma-derived exosomes (30µg protein) captured on
streptavidin and biotinylated anti-CD81 Ab-coated magnetic beads and
visualized with the EXO-FITC dye. Gate was set on single beads. The
white peak shows beads without exosomes, while the shaded peak
shows beads carrying exosomes visualized with the EXO-FITC dye. A
representative experiment of three performed with exosomes captured
from different AML patients’ plasma is shown.
to ELISA. Sonication was compared to freeze/thaw or to 10 M
urea and was found to be the most efficient method for release
of TGF-β1 from exosomes (data not shown). The sensitivity of
ELISA was 1.7 pg/mL, and recombinant TGF-β1 purchased from
R&D Systems was used as a positive control.
FUNCTIONAL STUDIES WITH ISOLATED EXOSOMES
Assays in which normal human NK cells were co-incubated with
exosomes to determine down-regulation of NKG2D on the sur-
face of these cells were previously described (4). Briefly, NK cells
(1× 106) were co-incubated for 48 h with exosomes (50µg) iso-
lated from AML plasma. Then, flow cytometry for NKG2D expres-
sion was performed and data expressed as mean fluorescence
intensity (MFI). NK cells incubated in medium were used as con-
trols. Isolation of human NK cells from normal donor buffy coats
using AutoMACS was also previously described (4). Expression
patterns of TGF-β1 on the isolated exosomes, as seen in western
blots, were correlated with the ability of these exosomes to inhibit
NKG2D expression on human NK cells upon co-incubation. Anti-
bodies to TGF-β (1µg/mL, MAB240, R&D Systems) or isotype
control antibodies added prior to co-incubation with exosomes
were used to prevent down-regulation of NKG2D expression on
NK cells. Recombinant human (rh) TGF-β1 (10 ng/mL) purchased
from R&D Systems was used as a positive control.
STATISTICAL ANALYSIS
Data were summarized by descriptive statistics: means and stan-
dard errors (SE) for continued variables or the frequency and
percentages for categorical variables. Statistical analyses were per-
formed using paired and unpaired two-tailed Student’s t -test.
When the data were not normally distributed (i.e., exosomal pro-
tein and TGF-β1 levels at AML diagnosis; Shapiro–Wilk normality
test, p< 0.005), Wilcoxon–Mann–Whitney rank sum test was per-
formed. A p value of <0.05 was considered to be statistically
significant.
RESULTS
EXOSOMES ISOLATED FROM THE PLASMA OF AML PATIENTS
Acute myeloid leukemia exosomes isolated patients’ plasma accu-
mulated at the density of 1.16–1.18 g/mL on continuous sucrose
density gradients (Figure 1A). They had a typical “donut-like”
appearance in a transmission electron microscope (Figure 1B),
were uniform in size (30–150 nm in diameter) by NanoSight
measurements (Figure 1C), and carried typical exosomal mark-
ers, e.g., CD81, as confirmed by western blots and also by flow
cytometry of exosomes captured on beads (Figure 1D). These
criteria are consistent with the characteristics ascribed to exo-
somes (11). Further, the exosomal fraction banding at the sucrose
density of 1.12–1.18 contained TGF-β1 pro-peptide and LAP
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(Figure 1A). The recovery of exosomes was 5× 1013 particles/mL
plasma (NanoSight).
EXOSOMAL PROTEIN LEVELS AT THE TIME OF AML DIAGNOSIS
The patients’ demographics and hematopathological characteris-
tics at the time of diagnosis and at different time points during
their leukemia treatment are presented in Table 1. The exosome
fractions isolated from AML patients’ plasma at diagnosis had a
considerably greater mean protein content (55.2± 13.8µg pro-
tein/mL plasma) than did exosome fractions isolated from the
plasma of NC (13.1± 2.4µg protein/mL plasma) with p< 0.009
(Figure 2A). Of interest, two patients had exosomal protein levels
that were highly elevated relative to the mean protein level for this
patient cohort (Figure 2A). These data point to large differences
in the exosomal protein content, ranging from normal to elevated,
among AML patients studied at diagnosis. However, neither the
percentage of blasts nor the patients’cytogenetic profiles correlated
with the exosomal protein levels at AML diagnosis. In addition, the
exosomal protein levels of AML patients whose blasts were found
to be reduced to <5% following a course of induction CT were
not significantly different from those in AML patients with residual
leukemia after a course of induction CT (78± 33 vs. 51± 24µg
protein/mL plasma at p= 0.5). Thus, exosomal protein levels at
Table 1 | Characteristics of AML patients included in this study.
AT AML DIAGNOSIS PRIORTOTREATMENT (n=16)
Median age (years) 64 (Range, 36–75)
Cytogenetic risk category at diagnosis
Unfavorable 9 (56%)
Intermediate 7 (44%)
Favorable 0
% Blasts in bone marrow at AML diagnosis 64 (Range, 38–93)
NEWLY DIAGNOSED AML PATIENT WHO RECEIVED INDUCTION
CHEMOTHERAPY (n=9)
Median age (years) 57 (Range, 36–70)
Cytogenetic risk category at diagnosis
Unfavorable 7 (64%)
Intermediate 4 (36%)
Favorable 0
% Blasts in bone marrow at AML diagnosis 72 (Range, 52–93)
AML PATIENTS IN CR DURING CONSOLIDATIONTHERAPY (n=10)
Median age (years) 51 (Range, 28–65)
Cytogenetic risk category at diagnosis
Unfavorable 2 (20%)
Intermediate 8 (80%)
Favorable 0
% Blasts in bone marrow at AML diagnosis 53 (Range, 21–83)
AML PATIENT IN CR IN LONG REMISSION AFTER CONSOLIDATION
THERAPY (n=5)
Median age (years) 46 (Range, 33–59)
Cytogenetic risk category at diagnosis
Unfavorable 0
Intermediate 4 (80%)
Favorable 1 (20%)
% Blasts in bone marrow at AML diagnosis 67 (Range, 50–82)
AML diagnosis did not appear to predict response to induction
therapy.
EFFECTS OF CT ON EXOSOMAL PROTEIN LEVELS
Of 9/16 newly diagnosed AML patients received induction CT. Fol-
lowing a course of induction CT, there was a significant reduction
in exosomal protein levels (to 23.8± 4.4µg protein/mL plasma
at p< 0.05; Figure 2A), concomitant with the reduction of AML
blasts in the bone marrow. In six patients, serial pre- and post-
induction plasma was available, and the paired data (Figure 2B)
confirmed a decrease in exosomal protein levels. The exosomal
protein levels on day 14 after the initiation of induction CT in
patients who had a reduction of leukemic blasts to <5% was
lower, but not significantly so, compared to the patients still having
residual leukemia (18.5± 5.8 vs. 30.8± 7.5µg protein/mL plasma;
p= 0.2).
During consolidation therapy with high dose cytarabine, the
exosomal protein levels in 10 patients who achieved CR was
higher (52.4± 8.9µg protein/mL plasma) relative to levels mea-
sured immediately post-induction CT (p< 0.02), reaching a mean
level close to that seen at AML diagnosis (Figure 2A). Two of these
10 patients went on to receive allogeneic hematopoietic cell trans-
plantation (allo-HCT) after two courses of consolidation CT. The
remaining eight patients completed four courses of consolidation
CT. Five/eight patients have subsequently relapsed. The exoso-
mal protein levels during consolidation CT were not significantly
different between the five patients who relapsed and those three
who remained in CR (mean values: 58.4 vs. 47.0µg protein/mL
plasma).
Exosomal protein levels of AML patients in long-term remis-
sion (>2 years after completing consolidation CT) were not signif-
icantly different from those seen in exosomes of NC (Figure 2A).
To date, with the median follow up of 48 months, none of these
five patients has relapsed.
In aggregate, these data suggest that significant changes in
the exosomal protein levels that occur after induction and dur-
ing consolidation CT could be useful for evaluating patients’
responses to CT.
TGF-β1 LEVELS IN AML EXOSOMES
We have previously shown that AML plasma-derived exosomes
carry TGF-β1 (4). In this study, we investigated changes in
exosome-associated TGF-β1 levels in relation to therapy given
to AML patients (Figure 2C). In general, TGF-β1 levels (mea-
sured after exosome sonication and acidification) tracked the
exosomal protein levels but were substantially better at discrim-
inating among AML patients at diagnosis and, especially, among
patients undergoing consolidation CT (compare Figures 2A,C).
As expected, TGF-β1 levels at AML diagnosis were higher than
those in exosomes of NC (Figure 2C). Following induction CT,
TGF-β1 levels were drastically reduced (p< 0.005). Importantly,
exosomal TGF-β1 levels were found to be elevated relative to
post-induction levels (p< 0.004) in patients receiving consoli-
dation CT (Figure 2C). Levels of active TGF-β1 were especially
high in four of the patients undergoing consolidation therapy
(two were high risk and underwent allo-HCT, one relapsed, and
one remains in remission). TGF-β1 levels in exosomes of AML
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FIGURE 2 | Protein levels and solubleTGF-β1 levels in exosomes
isolated from AML patients’ plasma. (A) Exosomal protein levels (in
microgram per milliliter plasma) for all patients in different cohorts: Diag,
at AML diagnosis; post IN, 14 days after starting induction CT; Cons,
during consolidation CT; lt-CR, long-term complete remission; NC,
normal control. (B) Exosomal protein levels in serial plasma samples
obtained from the same patients at AML diagnosis and 14 days after
starting induction CT. (C) Exosomal TGF-β1 levels measured by ELISA
after exosome sonication/acidification for patients in different cohorts. In
this and all subsequent figures, TGF-β1 values were normalized per
microgram exosomal protein in 1 mL plasma. The bars indicate mean
levels.
FIGURE 3 | A representative western blot ofTGF-β1 profiles in AML
exosomes. (A) Exosomes carry TGFβ1 pro-peptide consisting of
latency-associated peptide (LAP) covalently bound to the mature TGFβ1
(50 kDa), cleaved LAP (37 kDa) and mature TGFβ1 (25 kDa). Ten micrograms of
exosomal proteins were separated on SDS/PAGE gel and analyzed by western
blots using anti-TGFβ1 and anti-CD81 antibodies. (B) ActiveTGFβ1 levels in the
corresponding exosomes following their sonication/acidification. Results are
from ELISA performed as described in the Section “Materials and Methods.”
patients in long-term CR were not significantly different from
those of NC.
TGF-β1 PROFILES IN AML EXOSOMES
A representative western blot (Figure 3A) shows that AML exo-
somes carry the TGF-β1 pro-peptide consisting of the LAP cova-
lently bound to mature TGF-β1 (~50 kDa), cleaved LAP (~37 kDa)
and mature TGF-β1 (~25 kDa), which under reducing conditions
may dissociate into 2× 12.5 kDa chains (12, 13). In comparison
to exosomes obtained from the plasma of NC, those isolated
from AML patients’ plasma carry different forms of TGF-β1
(Figure 3A). Further, exosomes isolated from patients’ plasma
before, during, or after CT carry the three TGF-β1 forms (the
pro-peptide, LAP or active, mature form) in distinctly different
proportions. Also, these exosomes were found to contain differ-
ent levels of active TGF-β1, as measured by ELISA after exosome
sonication/acidification (Figure 3B). The levels of exosomal LAP
expression were generally, but not always, high at AML diagnosis
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FIGURE 4 |TGF-β1 profiles of four patients in long-term clinical
remission. Western blots for TGF-β1 and CD81, an exosomal marker, were
performed as described in the Section “Materials and Methods.” Few
exosomes were recovered from the plasma of patient #17, as indicated by a
nearly absent CD81 signal. Western blots of exosomes isolated from
plasma specimens of a representative AML patient and a NC are included
for comparisons. Protein levels and soluble TGF-β1 levels were measured in
the same exosomes and the respective values are shown below.
and also in exosomes of patients undergoing consolidation CT
(Figure 3). This observation implies that exosomal TGF-β1 levels
and TGF-β1 activation in exosomes might reflect the presence of
residual disease. Exosomes obtained from the plasma of four AML
patients in long-term clinical remission differed from each other
and from NC in the quality and quantity of the TGF-β1 cargo
(Figure 4).
FUNCTIONAL RELEVANCE OF TGF-β1 CARRIED BY EXOSOMES
To determine whether the distinct TGF-β1 profiles seen in exo-
somes obtained from AML patients at diagnosis and during ther-
apy are related to its biologic activity, purified normal human NK
cells (Figure 5A) were co-incubated with AML exosomes isolated
from the plasma of three different newly diagnosed AML patients
selected based on different exosomal TGF-β1 expression patterns
in western blots (Figure 5B). Linking the different TGF-β1 west-
ern blot patterns with biological functions mediated in vitro by
these exosomes, we observed that only exosomes of AML patient
#1 carrying high levels of mature TGF-β1 inhibited expression of
NKG2D in NK cells (Figure 5C). This inhibition was comparable
to that mediated by rhTGF-β1, and it was reversed by neutral-
izing antibody to TGF-β1. These data confirm the relevance of
TGF-β1 profiles in exosomes to their inhibitory activity vis a vis
human NK cells, which are known to be highly sensitive to TGF-β1
(4, 14–16).
DISCUSSION
Despite considerable progress and a relatively high morphologic
remission rate (approaching 70–80% in younger adults) with
intensive CT, only 30–40% of AML patients survive 5 years after
diagnosis. Many patients experience relapse, which is likely related
to the presence of minimal residual disease. It is important to be
able to identify AML patients who are at high risk of relapse and
need intensive post-remission treatment, and patients who can
potentially be cured with the currently available post-remission
regimens and are likely not to need additional therapy, thereby
reducing the treatment-related morbidity and mortality associated
with post-remission strategies.
In patients with melanoma and other solid tumors, total protein
levels of exosome fractions isolated from plasma were reported to
reflect disease stage, tumor burden, response to therapy, and even
survival, with patients characterized by a high exosomal protein
levels experiencing more advanced disease and shorter survival
(5–7). These reports provided a rationale for this cross-sectional
study of AML patients at the time of initial diagnosis prior to any
therapy and at different stages of their therapy, including patients
in complete clinical remission. Plasma-derived exosomes are a mix
of nanovesicles originating from various cells, including leukemic
blasts. As exosomes are known to be abundantly produced by
stressed cells (17), it seemed conceivable that in AML, exosomal
protein levels could reflect the extent of disease and correlate with
its relapse after therapy. Indeed, large differences were noted in
exosomal protein levels between patients at AML diagnosis, but as
previously reported by us (4), correlations with hematopatholog-
ical, genetic, and clinical data were not significant. Nevertheless,
the large differences seen in exosomal protein levels among AML
patients at diagnosis are intriguing and provide a rationale for
further exploration of a potential predictive value of such data.
In terms of therapy-related changes in exosomal protein levels,
it appears that significantly decreased protein levels in exosomal
fractions after induction CT were concomitant with the reduc-
tion of AML blasts in the bone marrow. Further, in some patients
receiving consolidation therapy who subsequently relapsed, exoso-
mal proteins were elevated, suggesting residual disease at the time
when leukemic blasts were undetectable in the bone marrow by
conventional methods. Importantly, exosomal protein levels were
not significantly elevated in the plasma of patients who achieve
long-term CR, suggesting that low exosomal protein levels might
be predictive of long-term disease free survival. These preliminary
data suggesting that exosomal proteins have a potential predictive
value in AML are obviously limited by the cross-sectional design
of our study and small numbers of patients in each cohort. Only
a few patients had serial samples available for the examination of
changes in exosomal protein levels during CT. Yet, these prelimi-
nary data suggested that serial monitoring of exosomes is likely to
be important in search for new tests with higher predictive values
for disease progression/relapse or responses to CT in AML.
We and others have shown that exosomes are involved in reg-
ulating functions of immune cells (18, 19) and thereby could
contribute to cancer progression/regression. Notably, TEX have
been implicated in inhibiting functions of immune cells either by
inducing apoptosis of CD8+ anti-tumor effector cells (20, 21),
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FIGURE 5 | Effects ofTGF-β1+ exosomes isolated from AML plasma
on NK cells. (A) Human CD3negCD56+ NK cells were isolated from the
peripheral blood of a normal volunteer and evaluated by flow cytometry.
(B) Western blots of TGF-β1 exosomes isolated from three AML
patients, each with a distinct TGF-β1 profile. CD81 served as an
exosomal marker. (C) After co-incubation of NK cells with exosomes
isolated from AML plasma as described in the Section “Materials and
Methods.” NKG2D expression (in MFI) was found to be down-regulated
only with exosomes of patient #1 and rhTGF-β1. Exosomes isolated from
a NC had no effect on NKG2D expression on NK cells. Anti-TGF-β1 Ab
protected NK cells from NKG2D down-regulation by exosomes of
patient #1. Shown is a representative experiment of three performed
with NK cells obtained from different donors. The shaded peaks
represent isotype controls.
down-regulating signaling in T and NK cells (22), inhibiting cyto-
toxicity (4, 23), or up-regulating functions of suppressor cells,
Treg, and/or MDSC (24–26). The role of plasma-derived exo-
somes in AML is consistent with down-regulation of NK activity,
largely but not entirely due to the presence of membrane-bound
TGF-β1 on these nanovesicles, as reported by us previously (4). It
appears that TGF-β1 is carried by exosomes isolated from almost
all AML patients’ plasma specimens we examined, and its exoso-
mal expression levels vary in patients tested at diagnosis vs. those
tested during or after CT. It also appears that exosomal TGF-β1
expression levels discriminate better than total exosomal protein
levels among patients, especially at diagnosis and during consoli-
dation CT. Further, patients in long-term clinical remission, who
had no residual disease, generally had low exosomal TGF-β1 lev-
els. Nevertheless, these patients’ exosomal TGF-β1 showed distinct
profiles, an indication that the observed distinct forms of TGF-β1
in AML exosomes obtained from the plasma of patients in CR
might have prognostic significance. Although exosomal TGF-β1 is
detected in western blots mainly in the latent form (LAP), it sig-
nals via the SMAD pathway when delivered to cells, as previously
shown by us (4). In studies with human NK cells co-incubated
with TGF-β1+ exosomes isolated from plasma of AML patients, we
demonstrated that their biological activity was mediated mainly
by the mature form of TGF-β1. This implies that exosomal latent
TGF-β1 is being converted into a mature, active form that medi-
ates biological activity when delivered to cells. The pro-peptide
and LAP forms of TGF-β1 abundantly present in isolated AML
exosomes, but not NC exosomes may be ready for utilization
and their processing to active TGF-β1 may be a link to TGF-
β1-mediated suppression of immune cells seen in AML (4). As
the expression pattern of TGF-β1 on exosomes is related to their
biological activity, it might serve as a biomarker of response to
therapy and might reflect the presence/absence of residual dis-
ease after therapy. Future profiling of serially harvested exosomes
when accompanied by functional analysis and correlations with
the relevant clinical data should confirm the value of monitor-
ing of the exosomal molecular content in AML. Already there is
evidence (27) that profiling the exosomal mRNA content from
treatment-naïve AML patients can reveal the presence of tran-
scripts relevant to AML prognosis (FLT3-ITD, NPM1), treatment
(FLT3-ITD, IGF-IR, CXCR4), and the leukemic niche function
(IGF-IR, CXCR4, MMP4).
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Perhaps the most critical question to be asked is whether AML
plasma-derived exosomes originate from leukemic blasts or from
another cellular source, such as transfusions of platelets or red
blood cells these patients receive. This is of great importance,
because if the former is true, then blast-derived exosomes should
qualify as very promising biomarkers of AML progression and
outcome. Our preliminary data based on immune capture of
AML exosomes with anti-CD34 antibodies suggest that TGF-β1
is carried by CD34+ exosomes and also by CD34− exosomes.
Regardless of their cellular source, however, TGF-β+ exosomes
exert profound biological effects on functions of immune and
non-immune cells, as previously reported (27–31). As such, they
are likely to influence cancer progression and might track with
responses to therapy. Further studies are warranted to adequately
assess the role of exosomes as potential diagnostic or prognostic
biomarkers in AML.
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